Facebook
X
LinkedIn
Forward2025 Vizient Pharmacy Network Meeting: Poster Session 2
Las Vegas, NV US
December 6, 2025
Sleep plays a critical role in cognitive function, metabolic regulation, and overall health, yet hospitalized patients often experience fragmented sleep due to disease burden, environmental noise, frequent monitoring, and nighttime medication administration. Older adults are particularly vulnerable to sleep disruption, as age-related changes reduce deep sleep and increase nocturnal awakenings. In the inpatient setting, routine administration of non-urgent medications during patient sleeping hours can contribute to unnecessary sleep fragmentation. Emerging evidence suggests that clustering medication administration during waking hours may improve sleep quality and potentially reduce delirium incidence. Research predicts that delirium affects up to 50% of hospitalized older adults and is associated with increased morbidity and mortality. However, limited data exist linking medication administration timing with sleep disruption and delirium risk. This study seeks to characterize the frequency and patterns of oral medication administration between 0100-0500 and evaluate how medications can be retimed to limit sleep disruptions.
Background: End stage renal disease (ESRD) is defined as the final stage of chronic kidney disease (CKD) where kidney function is unable to sustain life without dialysis or transplantation. Patients with CKD are at high risk for developing hypertension. In an observational study looking at the pre-hemodialysis (HD) blood pressure variation, risk of all-cause mortality, and major adverse cardiovascular events (MACE), greater pre-HD systolic blood pressure (SBP) variation was associated with an increased risk of primary outcomes. These risks emphasize the importance of improved blood pressure control in HD patients to decrease complications. Another comparison of whether holding versus administering antihypertensive medications before HD did not prove noninferiority. This data indicates that managing HD patient’s blood pressure is essential for reducing adverse outcomes.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as powerful therapies for type 2 diabetes, obesity, sleep apnea, and chronic kidney disease, offering meaningful improvements in glycemic control, weight reduction, and cardiovascular outcomes.1,2 There has been a steady increase] in prescribing of GLP-1 RAs beyond the diabetic population in the United States. New GLP-1 RA starts in individuals has increased more than 700% between 2019 and 2023.3 Despite these dramatic trends, there is limited insight into how GLP-1 prescribing is evolving within the Medicare and Medicaid population. The purpose of this study is to characterize national prescribing and utilization of GLP-1 molecules.
Purpose: Our emergency department implemented a cellulitis treatment algorithm including dalbavancin on August 1st, 2023. We sought to assess adherence to criteria for use and utilization overall.
Target Audience
- Pharmacists
- Pharmacy Technicians
- Other Healthcare Professionals
Learning Objectives
At the conclusion of this activity, pharmacists and pharmacy technicians should be able to:
- Assess the impact of pharmacist-led interventions on clinical outcomes, resource utilization, and value-based care
Mandalay Bay Las Vegas, NV
3950 S Las Vegas Blvd
Las Vegas, NV
89119
United States
FACULTY & PLANNERS
Faculty
Jamie Chan, PharmD
PGY-1 Pharmacy Resident
Memorial Hermann – Greater Heights
PGY-1 Pharmacy Resident
Memorial Hermann – Greater Heights
Caroline Ng, PharmD
PGY-1 Pharmacy Resident
Memorial Hermann – Texas Medical Center
PGY-1 Pharmacy Resident
Memorial Hermann – Texas Medical Center
Hannah Elfakih, PharmD
PGY-1 Pharmacy Resident
Memorial Hermann – Texas Medical Center
PGY-1 Pharmacy Resident
Memorial Hermann – Texas Medical Center
Gabrielle Ortiz, PharmD
PGY-1 Pharmacy Resident
Memorial Hermann – Texas Medical Center
PGY-1 Pharmacy Resident
Memorial Hermann – Texas Medical Center
Catherine Palmer, PharmD
PGY-2 Pharmacy Resident
Vizient, Inc.
PGY-2 Pharmacy Resident
Vizient, Inc.
Anthony Medina, PharmD
Pharmacy Fellow
Vizient, Inc.
Pharmacy Fellow
Vizient, Inc.
Jillian Mack, PharmD
PGY2 Infectious Diseases Pharmacy Resident
Nebraska Medicine
PGY2 Infectious Diseases Pharmacy Resident
Nebraska Medicine
Planners
Mital Desai, PharmD
Director, Pharmacy Network
Vizient, Inc.
Sybil Thomas, PharmD
AVP Member connections
Vizient, Inc.
Lauren E. McCree, MBA
Networks Manager, Pharmacy
Vizient, Inc.
Samantha Gordon, MS
CE Programs Manager
Vizient, Inc.
Marilu Kelly, MSN, RN, NPD-BC, CHCP
Director, Continuing Education
Vizient, Inc.
DISCLOSURE
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
Ineligible companies – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure Statements
Absence of Relevant Financial Relationships
None of the planners, faculty, or others in a position to control content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
[Insert name], speaker for this educational activity, is [nature of relationship(s)] for [insert name of the ineligible company(ies)].
[Insert name], speaker for this educational activity, is [nature of relationship(s)] for [insert name of the ineligible company(ies)].
All relevant financial relationships listed for these individual(s) have been mitigated.
All others in a position to control content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Statement of Content Validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA Off-Label Use
Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.
Off-label/unapproved drug uses or products are mentioned within this activity.
Low/absence of evidence-based topics are mentioned within this activity.
Disclaimer
The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
Joint Accreditation Statement
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation Statement(s)
Pharmacists (CPE)
Vizient, Inc. designates this live activity for a maximum of 0.75 contact hours for pharmacists.
Universal Activity Number: JA0006103-0000-25-316-L04-P
Pharmacy Technicians (CPE)
Vizient, Inc. designates this live activity for a maximum of 0.75 contact hours for pharmacy technicians.
Universal Activity Number: JA0006103-0000-25-316-L04-T
Other Healthcare Professionals (General CE Credit)
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
Available Credit
- 0.75 ACPE Pharmacist
- 0.75 ACPE Pharmacy Technician
Select the “Obtain Credit” button to access the activity evaluation and to claim CE Credit.
Please Note:
- If the "Register/Take Course" tab is displayed instead of the "Obtain Credit" tab, you must first login to proceed with the credit claim process.
- This activity requires learners to confirm their attendance using an activity code. An Access Denied error message indicates that your attendance was not recorded via SMS text or QR code scanning.
Please click here to enter the code you received at the end of the activity to verify your attendance if you have not already done so: https://continuingeducation.vizientinc.com/code
Required Hardware/software
The Vizient CE Learner Portal is compatible with most modern web browsers (such as Firefox, Google Chrome, Microsoft Edge, Apple Safari) and can also be accessed with mobile devices.